Azevan Pharmaceuticals
Azevan Pharmaceuticals is a clinical stage, small molecule drug development company focused on developing novel therapeutics for stress-related CNS disorders and neurodegenerative conditions. Their mission is to create next-generation pharmaceuticals that address unmet medical needs in neuropsychiatric and neurological disorders, leveraging their expertise in vasopressin receptor antagonists. Their vision is to provide effective treatments for conditions such as Huntington’s Disease, PTSD, TBI, and Intermittent Explosive Disorder, improving patient outcomes and quality of life.
Industries
Nr. of Employees
small (1-50)
Azevan Pharmaceuticals
Patents
Products
Oral CNS-penetrant selective V1a receptor antagonists (lead clinical candidates)
First-in-class, orally bioavailable, CNS-penetrant small-molecule antagonists selective for the vasopressin V1a receptor developed for stress-related psychiatric symptoms, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, intermittent explosive disorder, and traumatic brain injury.
Oral CNS-penetrant selective V1a receptor antagonists (lead clinical candidates)
First-in-class, orally bioavailable, CNS-penetrant small-molecule antagonists selective for the vasopressin V1a receptor developed for stress-related psychiatric symptoms, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, intermittent explosive disorder, and traumatic brain injury.
Services
End-to-end development of CNS-targeted small molecules including discovery, preclinical validation, early-phase clinical trials, and regulatory interactions performed in collaboration with academic and government networks.
End-to-end development of CNS-targeted small molecules including discovery, preclinical validation, early-phase clinical trials, and regulatory interactions performed in collaboration with academic and government networks.
Expertise Areas
- CNS small-molecule drug discovery
- GPCR pharmacology (vasopressin V1a)
- Translational neuroscience and neuroimaging
- Preclinical behavioral and TBI models
Key Technologies
- Small-molecule GPCR antagonists
- CNS-penetrant medicinal chemistry
- Oral bioavailability optimization
- Functional MRI (fMRI) for experimental medicine
News & Updates
Exploratory Phase 2 Trial in Huntington’s Disease patients meets primary, secondary, and exploratory endpoints
FDA grants Orphan Designation for the treatment of Huntington’s Disease with Azevan’s V1a receptor antagonist
FDA grants Fast Track status to Azevan’s SRX246 for the treatment of Huntington’s Disease
Irritability in HD Phase II Clinical Trial
The Phase II trial with SRX246 in Huntington's Disease patients exhibiting irritability was conducted and completed in collaboration with the NINDS NeuroNext network across 22 sites. The primary and secondary endpoints were met, and clinical benefit was demonstrated. SRX246 was granted an Orphan Designation.
Intermittent Explosive Disorder Phase II Clinical Trial
A Phase II clinical trial with SRX246 for the treatment of Intermittent Explosive Disorder has been completed, showing excellent tolerability, safety, and clinical benefit.
PTSD Phase II Clinical Trial
The Department of Defense awarded a grant to conduct a Phase II trial with SRX246 for PTSD, which is currently in progress in collaboration with Weill Cornell Medical College.
Exploratory Phase 2 Trial in Huntington’s Disease patients meets primary, secondary, and exploratory endpoints
FDA grants Orphan Designation for the treatment of Huntington’s Disease with Azevan’s V1a receptor antagonist
FDA grants Fast Track status to Azevan’s SRX246 for the treatment of Huntington’s Disease
Irritability in HD Phase II Clinical Trial
The Phase II trial with SRX246 in Huntington's Disease patients exhibiting irritability was conducted and completed in collaboration with the NINDS NeuroNext network across 22 sites. The primary and secondary endpoints were met, and clinical benefit was demonstrated. SRX246 was granted an Orphan Designation.
Intermittent Explosive Disorder Phase II Clinical Trial
A Phase II clinical trial with SRX246 for the treatment of Intermittent Explosive Disorder has been completed, showing excellent tolerability, safety, and clinical benefit.
PTSD Phase II Clinical Trial
The Department of Defense awarded a grant to conduct a Phase II trial with SRX246 for PTSD, which is currently in progress in collaboration with Weill Cornell Medical College.